Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0002001011-24-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-29 | 2024-02-28 | LGND | Espinoza Octavio | CFO | S - Sale+OE | $88.46 | -140 | 29.8K | -0.5% | -$12.4K |
| DM | 2024-02-29 | 2024-02-28 | LGND | Espinoza Octavio | CFO | M - OptEx | $56.62 | +1,264 | 29.4K | +4% | +$71.6K |
| D | 2024-02-29 | 2024-02-27 | LGND | Espinoza Octavio | CFO | A - Grant | $0.00 | +7,208 | 28.6K | +34% | $0 |
| DM | 2024-02-29 | 2024-02-28 | LGND | Espinoza Octavio | CFO | M - OptEx | $0.00 | -1,264 | 7,722 | -14% | $0 |
| D | 2024-02-29 | 2024-02-27 | LGND | Espinoza Octavio | CFO | A - Grant | $0.00 | +29.3K | 29.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-28 | S | D | 140 | $88.46 | 29,755 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-28 | M | A | 140 | $57.22 | 29,570 | D | — | — | |
| 3 | Common | Common Stock | 2024-02-28 | M | A | 325 | $58.49 | 29,895 | D | — | — | |
| 4 | Common | Common Stock | 2024-02-27 | A | A | 7,208 | $0.00 | 28,631 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
| 5 | Common | Common Stock | 2024-02-28 | M | A | 799 | $55.75 | 29,430 | D | — | — | |
| 6 | Derivative | Employee Stock Option (right to buy) | 2024-02-28 | M | D | 799 | $0.00 | 2,869 | D | $55.75 · — to 2030-02-13 | 799 Common Stock | (F2) As per the separation of OmniAb Inc. from the issuer, 2,039 stock options were vested and exercisable as of November 1, 2022, whereas 1,629 options vest in 16 substantially equal monthly installments beginning on November 13, 2022. |
| 7 | Derivative | Employee Stock Option (right to buy) | 2024-02-28 | M | D | 325 | $0.00 | 1,607 | D | $58.49 · — to 2027-02-24 | 325 Common Stock | (F4) The stock option is fully vested and exercisable. |
| 8 | Derivative | Employee Stock Option (right to buy) | 2024-02-27 | A | A | 29,272 | $0.00 | 29,272 | D | $89.20 · — to 2034-02-27 | 29,272 Common Stock | (F5) The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. |
| 9 | Derivative | Employee Stock Option (right to buy) | 2024-02-28 | M | D | 140 | $0.00 | 7,722 | D | $57.22 · — to 2030-10-01 | 140 Common Stock | (F3) As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022. |